

ANTIMICROBIAL RESISTANCE AND ONE-HEALTH

HEALTH POLICY NEWS

- ≡ **EU4Health Civil Society Alliance** - a [letter](#) to European Commission President nominee Ursula von der Leyen calling for the appointment of a Vice-President for Health, Wellbeing and Social Rights
- ≡ **Tamrisa** - [a new specialized pharma venture to tackle anti-microbial resistance through innovation, stewardship and access](#)
- ≡ **ECDC:**
 - [Pamela Rendi-Wagner begins as ECDC's new Director](#)
 - ECDC on Air - [Episode 52 - Diamantis Plachouras - Healthcare-associated infections](#)

SCIENTIFIC PUBLICATIONS

- ≡ **Drug Discovery Today** - [Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact](#)
- ≡ **The Lancet** - [Leveraging universal health coverage to leave no one behind in tackling AMR](#)
- ≡ **American Journal of Infection Control** - [Effectiveness of novel \$\beta\$ -lactams for *Pseudomonas aeruginosa* infection: A systematic review and meta-analysis](#)
- ≡ **Eurosurveillance:**
 - [Pathogen prioritisation for wastewater surveillance ahead of the Paris 2024 Olympic and Paralympic Games, France](#)
 - [Nosocomial transmission of *tet\(x3\)*, *bla_{NDM-1}* and *bla_{OXA-97}*-carrying *Acinetobacter baumannii* conferring resistance to eravacycline and omadacycline, the Netherlands, March to August 2021](#)
 - [First detection of a *Mycobacterium tuberculosis* XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023](#)

HEALTH POLICY BRIEFS

- ≡ **HERA** - [Assessment of the supply chain vulnerabilities for the first tranche of the Union list of critical medicines: Technical report](#)
- ≡ **Directorate-General for Research and Innovation (European Commission)** - [Science, research and innovation performance of the EU 2024](#)
- ≡ **IFPMA** - [Sustainable access to effective antibiotics position paper](#)

CONFERENCES AND WEBINARS

- ≡ **WHO** - [Addressing gender inequalities in national action plans on antimicrobial resistance](#), 11 July
- ≡ **Aquatic Pollutants** - [The SARA project - Surveillance of Emerging Pathogens and Antibiotic Resistance in Aquatic Ecosystems](#), 31 July
- ≡ **ECRAID** - ECRAID Young Investigator Workshop at ESCMID Global 2024, [recording available](#)
- ≡ **Microbiology Society** - [AMR In Focus Series](#), 16 September
- ≡ **EC** - Information session on MDR/IVDR for international regulators, [recording available](#)
- ≡ **ICARS-GARDP** - [Webinar: Strengthening antimicrobial stewardship for equitable access to novel antibiotics](#), 24 July
- ≡ **Biobot Analytics** - [Using Wastewater Data as Leading Indicators for Decision Making in the Healthcare Industry](#), 16 July
- ≡ **Singapore Centre for Environmental Life Sciences Engineering** - [Antimicrobial Resistance Symposium: Challenges and Solutions to the AMR Crisis](#), 9 – 11 September
- ≡ **Quadripartite** - [One Health Priority Research Agenda for AMR: Opportunities to foster the implementation of the agenda](#), 18 July

ANTIMICROBIAL RESISTANCE AND ONE-HEALTH

REGULATORY NEWS

- ≡ **MDCG 2020-16 Rev.3** - [Guidance on Classification Rules for *in vitro* Diagnostic Medical Devices under Regulation \(EU\) 2017/746](#) - July 2024

OPEN CONSULTATIONS

- ≡ **EFSA** - [Draft Scientific Report on review of the methodology used for the assessment of the short-term \(acute\) dietary exposure to pesticide residues in food \(IESTI methodology\)](#), deadline 23 August

TRAININGS

- ≡ **EC** - [Become a pro member of the EU Health Policy Platform with these four training sessions and Q&A](#), September-October
- ≡ **ESCMID**:
 - [Antibiotic Therapy and Antimicrobial Stewardship](#), 25 - 26 September, Ljubljana, Slovenia
 - [Maths against antimicrobial resistance](#), 23 - 24 October, Orléans, France
 - [Ethics in Infectious Diseases and Clinical Microbiology](#), 7 - 9 October

APPLICATIONS

- ≡ **FAO** - [Reduce the Need for Antimicrobials for Sustainable Agrifood System Transformation \(RENOFARM\) - Guidance for Membership Application](#)

LEGAL NOTICE

- ≡ *RESINFIT is financed entirely by Inserm and receives no external funding or sponsorship from private organizations.*
- ≡ *RESINFIT cannot provide any guarantees and cannot be held liable for any errors, inaccuracies or incompleteness of any information given on this digest or by any other third party.*
- ≡ *The views and opinions expressed by individual authors of articles, presentations or discussion/opinion papers etc. do not necessarily reflect those of RESINFIT.*
- ≡ *RESINFIT provides links to many websites created and maintained by third party public and/or private organizations. The presence of a link is not a RESINFIT endorsement of the site. Upon following a link to a third-party website, users are leaving RESINFIT and are subject to the privacy and security policies of the owners/sponsors of the third-party website(s). RESINFIT is not responsible for the information collection practices of external sites.*